Discontinuing pneumocystis carinii prophylaxis

New England Journal of Medicine

Volumn 344, Issue 3, 2001, Pages 222-223

  Girard, P M ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; MALOPRIM; PENTAMIDINE ISETHIONATE; VIRUS RNA;

BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; EDITORIAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TOXOPLASMOSIS; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; PNEUMONIA, PNEUMOCYSTIS; RNA, VIRAL;

EID: 0035905905     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101183440310     Document Type: Editorial

References (17)

1. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
2. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
3. Discontinuation of Pneumoeystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
4. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
5. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection
6. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
7. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: The changes in opportunistic prophylaxis study
8. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis
9. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
10. Intermittent trimethoprimsulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumoeystis pneumonia and toxoplasmosis in patients infected with HIV
11. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
12. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
13. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure
14. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus
15. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial
16. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patents who have a response to antiretroviral therapy
17. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant